117 related articles for article (PubMed ID: 11692906)
1. Coagulative modifications in patients with systemic sclerosis treated with iloprost or nifedipine.
Candela M; Pansoni A; Jannino L; Menditto VG; Natalini M; Ravaglia F; Da Lio L; Scorza R; Gabrielli A; Danieli G
Ann Ital Med Int; 2001; 16(3):170-4. PubMed ID: 11692906
[TBL] [Abstract][Full Text] [Related]
2. Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations.
Rehberger P; Beckheinrich-Mrowka P; Haustein UF; Sticherling M
Acta Derm Venereol; 2009; 89(3):245-9. PubMed ID: 19479119
[TBL] [Abstract][Full Text] [Related]
3. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
Cordioli E; Virgilio S; Ghirardi R; Martinelli M
Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
[TBL] [Abstract][Full Text] [Related]
4. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
5. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
6. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
7. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
[TBL] [Abstract][Full Text] [Related]
8. Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis.
Zardi EM; Picardi A; Ambrosino G; Fazio VM; Dobrina A; Frego M; Afeltra A; Lumachi F
In Vivo; 2006; 20(3):377-80. PubMed ID: 16724674
[TBL] [Abstract][Full Text] [Related]
9. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
[TBL] [Abstract][Full Text] [Related]
10. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
[TBL] [Abstract][Full Text] [Related]
11. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
Mittag M; Beckheinrich P; Haustein UF
Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
[TBL] [Abstract][Full Text] [Related]
12. Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study.
Rotondo C; Nivuori M; Chialà A; Praino E; Matucci Cerinic M; Cutolo M; Lapadula G; Iannone F
Scand J Rheumatol; 2018 Jul; 47(4):311-318. PubMed ID: 29409385
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of haemostatic parameters and circadian variations of the haemostatic system in patients with systemic sclerosis and Raynaud's phenomenon.
Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Sottilotta G; Larosa D; Barbera N
Panminerva Med; 2000 Mar; 42(1):7-9. PubMed ID: 11019597
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases.
Zulian F; Corona F; Gerloni V; Falcini F; Buoncompagni A; Scarazatti M; Martini G; Zacchello F
Rheumatology (Oxford); 2004 Feb; 43(2):229-33. PubMed ID: 12923288
[TBL] [Abstract][Full Text] [Related]
15. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M
Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic events in patients with systemic sclerosis treated with iloprost.
Tedeschi A; Meroni PL; Del Papa N; Salmaso C; Boschetti C; Miadonna A
Arthritis Rheum; 1998 Mar; 41(3):559-60. PubMed ID: 9506585
[No Abstract] [Full Text] [Related]
17. Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine.
Della Bella S; Molteni M; Mascagni B; Zulian C; Compasso S; Scorza R
Clin Exp Rheumatol; 1997; 15(2):135-41. PubMed ID: 9196864
[TBL] [Abstract][Full Text] [Related]
18. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis.
Cerinic MM; Valentini G; Sorano GG; D'Angelo S; Cuomo G; Fenu L; Generini S; Cinotti S; Morfini M; Pignone A; Guiducci S; Del Rosso A; Kalfin R; Das D; Marongiu F
Semin Arthritis Rheum; 2003 Apr; 32(5):285-95. PubMed ID: 12701039
[TBL] [Abstract][Full Text] [Related]
19. Iloprost infusion does not reduce oxidative stress in systemic sclerosis.
Volpe A; Biasi D; Caramaschi P; Bambara LM; Carletto A; Degan M; Minuz P
Rheumatol Int; 2008 Feb; 28(4):335-7. PubMed ID: 17704920
[TBL] [Abstract][Full Text] [Related]
20. The anti-platelet effect of nifedipine in patients with systemic sclerosis.
Rademaker M; Meyrick Thomas RH; Kirby JD; Kovacs IB
Clin Exp Rheumatol; 1992; 10(1):57-62. PubMed ID: 1551280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
